logo-loader

Highlight Therapeutics aim to extend the benefit of immunotherapies for patients

Published: 15:26 25 Nov 2020 GMT

Highlight Therapeutics' Marisol Quintero talks to Proactive London's Katie Pilbeam about their intention to extend the benefit of immunotherapies for patients who are not benefiting right now.

Quintero explains the plans for clinical trials of its lead product candidate BO-112.

The company recently announced that they have entered a second Phase II trial collaboration with a subsidiary of Merck & Co. And there are currently three ongoing trials in total.

Highlight Therapeutics present developments for lead drug candidate BO-112...

Marisol Quintero, CEO of Highlight Therapeutics joins Proactive London for a catch up after a busy 2021.  At the end of the year, the firm reported excellent clinical data for BO-112 in patients with melanoma, Quintero talks through the next steps for the development of the...

on 25/2/22